Particularly, overexpression of Fbxo4 effectively enhances the sensitivity of NSCLC cells to chemotherapeutic compounds, including cisplatin or paclitaxel, highlighting the therapeutic potential by targeting Fbxo4-Mcl-1 signaling for treating NSCLC. Here, MCL1 is linked to non-small cell lung carcinoma.